Phase III study of LCZ 696 meets endpoint for Heart Failure - Novartis
Novartis has presented outline data revealing a reduction in cardiovascular (CV) deaths with LCZ 696 in patients with Heart Failure with reduced ejection fraction (HF-REF). The 8,442 patient Phase III study, PARADIGM-HF, was specifically designed to see if LCZ 696 could increase survival over and above what can be achieved with ACE-inhibitor enalapril in addition to current best treatment in HF-REF patients.
The study met the primary endpoint showing LCZ 696 reduced heart failure hospitalizations along with CV deaths. The primary outcome is a composite of time to first occurrence of either cardiovascular death or heart failure hospitalization, and is the largest heart failure study ever done. Detailed data will be presented in 7 papers at the European Society of Cardiology Congress 2014.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.